Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer. 2016 Mar 9;122(9):1312–1337. doi: 10.1002/cncr.29936

TABLE 1.

Surveillance, Epidemiology, and End Results (SEER) Cancer Incidence Rate Trends With Joinpoint Analyses From 1992 to 2012 for the Most Common Cancers, by Sex, for All Racial and Ethnic Groups Combineda

Sex/Cancer Site or Type Joinpoint Analyses (1992–2012)b
Trend 1
Trend 2
Trend 3
Trend 4
AAPCc
Years APCd Years APCd Years APCd Years APCd 2003–2012 2008–2012
All sitese
 Both sexes 1992–1994   −3.1f 1994–1998   0.4 1998–2009 −0.4f 2009–2012 −2.3f −1.0g −1.8g
  (Delay-adjusted) 1992–1994   −3.1f 1994–1998   0.4 1998–2009 −0.3f 2009–2012 −1.5f −0.7g −1.2g
 Men 1992–1994   −5.7f 1994–2009 −0.5f 2009–2012 −4.1f −1.7g −3.2g
  (Delay-adjusted) 1992–1994   −5.8f 1994–2009 −0.5f 2009–2012 −3.1f −1.4g −2.5g
 Women 1992–1998     0.7f 1998–2012 −0.3f −0.3g −0.3g
  (Delay-adjusted) 1992–1998     0.8f 1998–2003 −0.6 2003–2012   0.0   0.0   0.0
 Children (ages 0–14 years) 1992–2012     0.7f   0.7g   0.7g
  (Delay-adjusted) 1992–2012     0.8f   0.8g   0.8g
 Children (ages 0–19 years) 1992–2012     0.7f   0.7g   0.7g
  (Delay-adjusted) 1992–2012     0.8f   0.8g   0.8g
Top 17 cancers among menh
 Prostate 1992–1995 −11.1f 1995–2000   2.1 2000–2010 −2.0f 2010–2012 −12.4f −4.4g −7.3g
  (Delay-adjusted) 1992–1995 −11.1f 1995–2000   2.1 2000–2010 −1.8f 2010–2012 −11.2f −4.0g −6.6g
 Lung and bronchus 1992–2009   −1.9f 2009–2012 −4.2f −2.7g −3.6g
  (Delay-adjusted) 1992–2009   −1.9f 2009–2012 −3.3f −2.4g −3.0g
 Colon and rectum 1992–1995   −2.6f 1995–1998   1.4 1998–2008 −2.5f 2008–2012 −4.0f −3.2g −4.0g
  (Delay-adjusted) 1992–1995   −2.6f 1995–1998   1.4 1998–2008 −2.5f 2008–2012 −3.6f −3.0g −3.6g
 Urinary bladder 1992–2007     0.1 2007–2012 −1.7f −0.9g −1.7g
  (Delay-adjusted) 1992–2007     0.1 2007–2012 −1.2f −0.6g −1.2g
 Melanoma of the skin 1992–2008     2.6f 2008–2012 −0.4   1.2g −0.4
  (Delay-adjusted) 1992–1996     5.0f 1996–2012   2.0f   2.0g   2.0g
 Non-Hodgkin lymphoma 1992–1995     2.8 1995–1998 −2.1 1998–2010   0.6f 2010–2012 −4.1 −0.5 −1.8
  (Delay-adjusted) 1992–1995     2.8 1995–1998 −2.2 1998–2010   0.7f 2010–2012 −2.8 −0.1 −1.1
 Kidney and renal pelvis 1992–2004     1.9f 2004–2008   4.4f 2008–2012 −1.4   1.5g −1.4
  (Delay-adjusted) 1992–1999     1.1f 1999–2008   3.2f 2008–2012 −0.1   1.7g −0.1
 Oral cavity and pharynx 1992–2001   −1.8f 2001–2012   0.2   0.2   0.2
  (Delay-adjusted) 1992–2003   −1.5f 2003–2012   0.8f   0.8g   0.8g
 Leukemia 1992–2012     0.1   0.1   0.1
  (Delay-adjusted) 1992–2006     0.2 2006–2012   1.8f   1.3g   1.8g
 Pancreas 1992–2003     0.0 2003–2006   2.9 2006–2012   0.1   1.0   0.1
  (Delay-adjusted) 1992–2001     0.0 2001–2012   1.2f   1.2g   1.2g
 Liver and intrahepatic bile duct 1992–1999     4.6f 1999–2002   0.5 2002–2007   5.4f 2007–2012   1.8f   3.4g   1.8g
  (Delay-adjusted) 1992–2012     3.7f   3.7g   3.7g
 Stomach 1992–2012   −1.7f −1.7g −1.7g
  (Delay-adjusted) 1992–2012   −1.7f −1.7g −1.7g
 Esophagus 1992–2012   −0.2 −0.2 −0.2
  (Delay-adjusted) 1992–2012   −0.2 −0.2 −0.2
 Brain and other nervous system 1992–2012   −0.3f −0.3g −0.3g
  (Delay-adjusted) 1992–2012   −0.2f −0.2g −0.2g
 Myeloma 1992–2012     0.7f   0.7g   0.7g
  (Delay-adjusted) 1992–2006     0.4 2006–2012   3.0f   2.1g   3.0g
 Thyroid 1992–1995   −3.0 1995–2012   5.2f   5.2g   5.2g
  (Delay-adjusted) 1992–1995   −3.2 1995–2012   5.3f   5.3g   5.3g
 Larynx 1992–2003   −3.1f 2003–2012 −1.9f −1.9g −1.9g
  (Delay-adjusted) 1992–2003   −3.2f 2003–2012 −1.7f −1.7g −1.7g
Top 18 cancers among womenh
 Breast 1992–1999     1.3f 1999–2004 −2.2f 2004–2012   0.2 −0.1   0.2
  (Delay-adjusted) 1992–1999     1.3f 1999–2004 −2.2f 2004–2012   0.3   0.0   0.3
 Lung and bronchus 1992–2007     0.0 2007–2012 −2.4f −1.3g −2.4g
  (Delay-adjusted) 1992–2007     0.0 2007–2012 −1.9f −1.1g −1.9g
 Colon and rectum 1992–1995   −1.8f 1995–1998   1.8 1998–2008 −2.0f 2008–2012 −4.1f −2.9g −4.1g
  (Delay-adjusted) 1992–1995   −1.8f 1995–1998   1.8 1998–2008 −2.0f 2008–2012 −3.8f −2.8g −3.8g
 Corpus and uterus, NOS 1992–1997     0.8 1997–2004 −0.8 2004–2012   1.8f   1.5g   1.8g
  (Delay-adjusted) 1992–2006   −0.1 2006–2012   2.3f   1.5g   2.3g
 Thyroid 1992–1999     4.1f 1999–2009   6.9f 2009–2012   1.4   5.0g   2.7g
  (Delay-adjusted) 1992–1999     4.1f 1999–2009   6.9f 2009–2012   1.8   5.2g   3.0g
 Non-Hodgkin lymphoma 1992–2004     1.3f 2004–2012 −0.8f −0.5 −0.8g
  (Delay-adjusted) 1992–2004     1.3f 2004–2012 −0.4 −0.2 −0.4
 Melanoma of the skin 1992–1997     4.0f 1997–2010   1.6f 2010–2012 −3.1   0.5 −0.8
  (Delay-adjusted) 1992–2005     2.4f 2005–2012   0.5   0.9g   0.5
 Ovarye 1992–2012   −1.0f −1.0g −1.0g
  (Delay-adjusted) 1992–2012   −0.9f −0.9g −0.9g
 Kidney and renal pelvis 1992–1998     1.2 1998–2008   3.1f 2008–2012 −1.3   1.2g −1.3
  (Delay-adjusted) 1992–2000     1.6f 2000–2007   3.6f 2007–2012 −0.1   1.5g −0.1
 Pancreas 1992–2012     0.7f   0.7g   0.7g
  (Delay-adjusted) 1992–1999   −0.1 1999–2012   1.1f   1.1g   1.1g
 Leukemia 1992–2012     0.3f   0.3g   0.3g
  (Delay-adjusted) 1992–2012     0.7f   0.7g   0.7g
 Urinary bladder 1992–2004   −0.2 2004–2012 −1.2f −1.1g −1.2g
  (Delay-adjusted) 1992–2004   −0.2 2004–2012 −1.1f −1.0g −1.1g
 Cervix uteri 1992–2012   −2.4f −2.4g −2.4g
  (Delay-adjusted) 1992–2012   −2.4f −2.4g −2.4g
 Oral cavity and pharynx 1992–2012   −0.7f −0.7g −0.7g
  (Delay-adjusted) 1992–2005   −1.1f 2005–2012   0.5   0.1   0.5
 Brain and other nervous system 1992–2012   −0.2 −0.2 −0.2
  (Delay-adjusted) 1992–2012     0.0   0.0   0.0
 Myeloma 1992–2012     0.4f   0.4g   0.4g
  (Delay-adjusted) 1992–2012     0.7f   0.7g   0.7g
 Stomach 1992–2012   −0.7f −0.7g −0.7g
  (Delay-adjusted) 1992–2012   −0.6f −0.6g −0.6g
 Liver and intrahepatic bile duct 1992–1996     6.9f 1996–2012   2.4f   2.4g   2.4g
  (Delay-adjusted) 1992–2012     3.0f   3.0g   3.0g

Abbreviations: AAPC, average annual percent change; APC, annual percent change; NOS, not otherwise specified.

a

Source: Surveillance, Epidemiology, and End Results (SEER)-13 areas covering about 14% of the US population (Connecticut, Hawaii, Iowa, Utah, and New Mexico; the Alaska Native Tumor Registry; rural Georgia; and the metropolitan areas of San Francisco, Los Angeles, San Jose-Monterey, Detroit, Atlanta, and Seattle-Puget Sound).

b

Joinpoint analyses with up to 3 joinpoints yielding up to 4 trend segments (Trends 1–4) were based on rates per 100,000 persons and were age-adjusted to the 2000 US standard population (19 age groups: ages <1 year, 1–4 years, 5–9 years, …, 80–84 years, and ≥85 years; Census publication p25-1130 [US Bureau of the Census, Current Population Reports, p25-1130. Washington, DC: US Government Printing Office; 2000]). For joinpoint analysis, the Joinpoint Regression Program was used (version 4.2.0.0, April 2015; Statistical Research and Applications Branch, National Cancer Institute, Bethesda, MD).

c

The AAPC is a weighted average of the APCs calculated by joinpoint regression.

d

The APC is based on rates that were age-adjusted to the 2000 US standard population (19 age groups; Census publication p25-1130).

e

All sites exclude myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.

f

The APC is statistically significantly different from zero (2-sided t test; P < .05).

g

The AAPC is statistically significantly different from zero (2-sided Z test; P < .05).

h

Cancers are listed in descending rank order of sex-specific, age-adjusted incidence rates for 2008 through 2012 for all racial and ethnic groups combined (using data from the National Program of Cancer Registries [NPCR] and SEER Program areas reported by the North American Association of Central Cancer Registries [NAACCR] as meeting high-quality incidence data standards for 2008–2012). More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group.